

BC PharmaCare Drug Information

The drug below is being considered for possible coverage under the B.C. PharmaCare program. PharmaCare is a government-funded drug plan that helps British Columbians with the cost of eligible prescription drugs and specific medical supplies. For more information on PharmaCare, visit [Ministry of Health - PharmaCare](#).

PharmaCare reviews each drug for treating a specific illness or medical condition (known as an “indication”). If a decision is made to cover the drug, it will be only for that illness or condition.

In some cases, PharmaCare may cover a drug only for people who have the illness or condition and have not responded to other drugs used to treat that illness or condition.

For more information on PharmaCare’s drug coverage review process, see the last page of this information sheet.

Information about the drug	
Generic name (scientific name)	daclatasvir
Brand name	Daklinza™
Manufacturer	Bristol-Myers Squibb Canada
Indication	Daklinza™ is indicated for the treatment of chronic (lasting a long time) Hepatitis C infection.
Has the drug been reviewed by the Common Drug Review (CDR) (see the note below this table.)	Yes For more information about the CDR’s review of daclatasvir (Daklinza™), you can Search the CDR Reports .
Public input start date	Wednesday, July 22, 2015
Public input closing date	Wednesday, August 19, 2015 AT MIDNIGHT
How is the drug taken?	Daklinza™ is taken orally (by mouth)
How often is the drug is taken?	Daklinza™ is taken once daily

Information about the drug	
General drug and/or drug study information	<p>Daklinza™ is used to treat chronic Hepatitis C (CHC) infection in adults. Daklinza™, in combination with other types of anti-hepatitis C virus (anti-HCV) drugs, blocks multiple steps in the replication process of the Hepatitis C virus (HCV). This prevents the virus particles from duplicating themselves, allowing the body to clear (remove) the virus from the blood.</p> <p>Daklinza™ has been shown to cure CHC infection in the majority of patients. Virologic cure means the HCV is cleared from the patient’s blood (remains at an undetectable level) when measured 3 months after finishing all treatment.</p> <p>Studies looked at the following common outcomes to assess if Daklinza™ is helpful and safe for the treatment of CHC:</p> <ul style="list-style-type: none"> • The effectiveness of the Hepatitis C treatment using Sustained Virologic Response (SVR) measurement which measures the HCV in the blood twelve weeks after the end of treatment • The return of the disease or relapse after achieving cure • Quality of life • Bad reactions • Serious bad reactions • Withdrawals due to bad reactions
Other considerations	None

Note:

The Common Drug Review (CDR) is a national organization that reviews drugs on behalf of Canadian public sector plans when manufacturers want to have the jurisdictions provide coverage for the drugs. For detailed information on B.C. PharmaCare’s drug review process, including the role of the CDR in that process, see [The Drug Review Process in B.C. - Overview](#).

Cost of the drug under review compared to other drugs used to treat the same indication			
generic name (Brand Name) of Drug Comparator	PharmaCare Status (if and how the drug is already covered)	Usual Dose	Cost of Therapy for 1 course of combination therapy
daclatasvir (Daklinza™) plus sofosbuvir (Sovaldi™) with or without ribavirin (RBV)	Under Review for genotype 1, 2, and 3	daclatasvir: once daily sofosbuvir: once daily ribavirin: twice daily	\$95,550 to \$191,100 (for genotype 1,2 or 3 without RBV) \$196,362 (for genotype 2 or 3 with RBV)

Cost of the drug under review compared to other drugs used to treat the same indication			
generic name (Brand Name) of Drug Comparator	PharmaCare Status (if and how the drug is already covered)	Usual Dose	Cost of Therapy for 1 course of combination therapy
sofosbuvir (Sovaldi™) in combination with peginterferon alfa plus RBV for genotype 1 sofosbuvir (Sovaldi™) in combination with RBV for genotype 2 or 3	Limited Coverage for genotype 1, 2 and 3	Once daily (peginterferon alfa: once weekly; ribavirin: twice daily)	\$62,739 (for genotype 1) \$61,039 to \$61,696 (for genotype 2) \$122,077 to \$123,392 (for genotype 3)
ombitasvir-paritaprevir- ritonavir and dasabuvir (Holkira™ Pak) with or without RBV	Under Review for genotype 1	Two times daily (ribavirin: twice daily)	\$58,653 to \$117,306 ^a (for genotype 1)
ledipasvir-sofosbuvir (Harvoni™)	Limited Coverage for genotype 1	Once daily	\$46,900 to \$140,702 (for genotype 1)
simeprevir (Galexos™) in combination with peginterferon alfa plus ribavirin	Limited Coverage for genotype 1	Once daily (peginterferon alfa: once weekly; ribavirin: twice daily)	\$48,303 to \$58,278 (for genotype 1)
boceprevir (Victrelis™, Victrelis™ Triple) in combination with peginterferon alfa plus ribavirin	Limited Coverage for genotype 1	Three times daily (peginterferon alfa: once weekly; ribavirin: twice daily)	\$38,098 to \$68,460 (for genotype 1)
pegIFN/RBV (Pegasys RBV™, Pegatron™, Pegatron™ Redipen)	Limited Coverage for genotype 2, 3, 4, 5 and 6	peginterferon alfa: once weekly; ribavirin: twice daily	\$9,975 to \$11,262 (for genotype 2 or 3)

^a RBV (Moderiba™) is provided free of charge from the manufacturer when prescribed in combination with Holkira™ Pak

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(Council\)](#) gives advice to the Ministry. The Council looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- whether the drug is a good value for the people of B.C. and what it costs
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence--informed advice of the Council
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, visit: [The Drug Review Process in B.C. - Overview](#).

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.